AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7596370
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunosuppressive therapy (prednisone with either cyclosporine or azathioprine) for 24 weeks
Trial: 9111
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg bromazepam p.o.
Trial: 31033512
Drug: Therapeutic anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic anticoagulation with heparin (target activated partial thromboplastin time between 50 and 70 s)
Trial: 31033512
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose heparin (up to 12,000 U/24 hr aiming for activated partial thromboplastin time < 45 s)
Trial: 3734264
Drug: Therapeutic anticoagulation
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic anticoagulation with heparin
Trial: 31033512
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose heparin
Trial: 29045553
Drug: S-1 (80-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle)
Trial: 29045553
Drug: Docetaxel (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60 mg/m2 in Japan, 75 mg/m2 at all other study sites; day 1 in a 3-week cycle)
Trial: 23589097
Drug: Tailored home‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored home‐based exercise (HE; 1‐hour training), twice a week for 1 year
Trial: 23589097
Drug: Group‐based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group‐based exercise (GE; 4‐hour sessions with approximately 1‐hour training), twice a week for 1 year
Trial: 21159803
Drug: 150 ml
RxNorm normalized name: REBYOTA 150 ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 ml of intravenous contrast at a rate of 2.5 ml s(‐1)
Trial: 21159803
Drug: 100 ml
RxNorm normalized name: PVC IV Bag 100 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 ml of intravenous contrast at a rate of 2 ml s(‐1)
Trial: 12949996
Drug: Gepirone immediate-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone immediate-release (gepirone-IR)
Trial: 12949996
Drug: Gepirone extended-release
RxNorm normalized name: gepirone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone extended-release (gepirone-ER, types 1, 2, and 3)
Trial: 12949996
Drug: Gepirone extended-release
RxNorm normalized name: gepirone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gepirone extended-release (gepirone-ER)
Trial: 8150761
Drug: Cefepime 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefepime 2.0 g bd i.v.
Trial: 8150761
Drug: Ceftazidime 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2.0 g tid i.v.
Trial: 25176615
Drug: Entecavir 0.5mg
RxNorm normalized name: ENTECAVIR 0.5MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entecavir 0.5mg daily
Trial: 18431235
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid therapy (15 mg/day of methyltertrahydrofolate for 1 year)
Trial: 18431235
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid therapy in high-risk subgroup (older recipients and those with coronary artery disease)
Trial: 18431235
Drug: Folic acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Folic acid therapy in lower-risk subgroup
Trial: 12718214
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (20 mg/day for 20 days)
Trial: 12718214
Drug: Inhaled benacort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled benacort (400 micrograms twice a day for 20 days)
Trial: 8471327
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant combination chemotherapy (AMF); 5‐fluorouracil 500 mg/m2, doxorubicin 40 mg/m2, mitomycin C 6 mg/m2 (n = 30) once every 3 weeks for six cycles
Trial: 8471327
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no adjuvant chemotherapy) (n = 31)
Trial: 8471327
Drug: Postoperative adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative adjuvant combination chemotherapy (AMF)
Trial: 3898908
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (80 micrograms in the epidural test dose of bupivacaine)
Trial: 3898908
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (infusion designed to produce comparable plasma concentrations)
Trial: 24132613
Drug: Sitagliptin 100
RxNorm normalized name: SITagliptin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin 100 mg daily
Trial: 28594249
Drug: School nurse-administered
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School nurse-administered inhaled corticosteroids (ICS)
Trial: 28594249
Drug: Control (home-administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (home-administered ICS)
Trial: 25891550
Drug: Intramuscular interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular interferon beta-1a (IM IFNβ‐1a) 30 μg
Trial: 22857881
Drug: Nutritional support
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional support with whey peptide and low-intensity exercise therapy
Trial: 20300048
Drug: Other antihypertensive
RxNorm normalized name: Other antihypertensives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antihypertensive drug monotherapies
Trial: 18400141
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 microg kg(‐1) in 10 mL normal saline)
Trial: 18400141
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 microg kg(‐1) in 10 mL normal saline)
Trial: 11985532
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose immunosuppression (after tapering)
Trial: 9307633
Drug: 0.3% carbomer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% carbomer gel
Trial: 9307633
Drug: placebo (mannitol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (mannitol solution with benzalkonium chloride 0.008%)
Trial: 9307633
Drug: carbomer gel
DrugBank: Carbomer (DB15649)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: carbomer gel and placebo
Trial: 27309886
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (240 mg in 125 mL saline solution)
Trial: 27309886
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (125 mL saline solution)
Trial: 18068284
Drug: Combined treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatments (Methylphenidate + Psychosocial treatments)
Trial: 18068284
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (Methylphenidate, Psychosocial treatments, Combined treatments)
Trial: 15528979
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of GW572016
Trial: 15528979
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of GW572016 (25 mg, 100 mg, 175 mg)
Trial: 12629229
Drug: alpha‐[11C] methyl‐L‐tryptophan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐[11C] methyl‐L‐tryptophan (alpha‐MTrp) PET
Trial: 8561642
Drug: Heparin-coated oxygenator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated oxygenator
Trial: 24060179
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of EGFR/p16
Trial: 21263371
Drug: Cefazolin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (two doses during removal of the catheter)
Trial: 7404301
Drug: No antimicrobial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antimicrobial agent (control group)
Trial: 19208352
Drug: Low-carbohydrate (LC)
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-carbohydrate (LC) diet (<50 g/day)
Trial: 19208352
Drug: Low-fat, high-carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat, high-carbohydrate (HC) diet (>180 g/day)
Trial: 18667140
Drug: Various nonpharmacologic
RxNorm normalized name: various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various nonpharmacologic interventions and therapies tried by patients, including assessment of success rates and patient function.
Trial: 15363824
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment (20 nonpharmacologic, 36 beta‐blockers, 33 angiotensin receptor blocker)
Trial: 15363824
Drug: Antihypertensive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive treatment after 12 months
Trial: 11181662
Drug: IV carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV carboplatin (area under curve 9) every 28 days for two courses, then IV paclitaxel 135 mg/m(2) over 24 hours followed by intraperitoneal (IP) cisplatin 100 mg/m(2) every 3 weeks for six courses
Trial: 11181662
Drug: IV cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV cisplatin 75 mg/m(2) every 3 weeks for six courses plus IV paclitaxel 135 mg/m(2) over 24 hours
Trial: 9692280
Drug: Organization and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Organization and administration issues studies
Trial: 3931107
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg lorazepam
Trial: 11960
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg papaveretum/400 mug hyoscine
Trial: 28185260
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg sugammadex (Group S)
Trial: 28185260
Drug: 0.35 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35 mg/kg neostigmine and 0.02 mg/kg atropine (Group N)
Trial: 23380907
Drug: Laser acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser acupuncture as adjunct to reversible occlusal splint therapy
Trial: 23380907
Drug: Placebo laser
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo laser associated with occlusal splint therapy
Trial: 4037555
Drug: Weekly pulse
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly pulse methotrexate
Trial: 28887640
Drug: G10 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G10 group received two IV doses of 10 mg/kg of TXA
Trial: 28887640
Drug: G20 group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G20 group received two doses of 20 mg/kg of TXA
Trial: 25263395
Drug: Red wine
RxNorm normalized name: Red wine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Red wine (12% ethanol, 1758 mg/L total polyphenols) for 4 weeks
Trial: 23051744
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) 7.5 g divided into three daily doses
Trial: 15715969
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 100 mg, single dose
Trial: 15715969
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 200 mg, single dose
Trial: 15715969
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) 400 mg, single dose
Trial: 14609883
Drug: Olanzapine, 5
RxNorm normalized name: Olanzapine, 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine, 5 to 20 mg/d
Trial: 14609883
Drug: Olanzapine-fluoxetine combination,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine-fluoxetine combination, 6 and 25, 6 and 50, or 12 and 50 mg/d
Trial: 14609883
Drug: Olanzapine-fluoxetine vs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine-fluoxetine vs Olanzapine
Trial: 14609883
Drug: Treatment-emergent mania
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment-emergent mania
Trial: 14609883
Drug: Adverse events
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adverse events for olanzapine-fluoxetine
Trial: 18614998
Drug: HAART (highly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART (highly active antiretroviral therapy)
Trial: 1375598
Drug: Synthetic porcine
RxNorm normalized name: Secretin synthetic porcine
DrugBank: Secretin porcine (DB09527)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Synthetic porcine galanin (0.5 mg in 100 mL saline)
Trial: 1375598
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (100 mL saline)
Trial: 3893700
Drug: 1% Clotrimazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% Clotrimazole cream
Trial: 31142044
Drug: 10 mg-Zn/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg-Zn/day
Trial: 31142044
Drug: 5 mg-Zn/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg-Zn/day
Trial: 28991918
Drug: No stool
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No stool testing and placebo treatment
Trial: 25620670
Drug: Step-up treatment
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step-up treatment after endoscopic recurrence
Trial: 23521325
Drug: Avanafil 100/200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avanafil 100/200 mg
Trial: 11773989
Drug: Eprosartan 300
RxNorm normalized name: eprosartan 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eprosartan 300 mg twice daily
Trial: 9924262
Drug: Lower-carbohydrate test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-carbohydrate test meal (0.5 g fat/kg body weight + 17 g carbohydrate as lactose)
Trial: 9924262
Drug: Higher-carbohydrate test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-carbohydrate test meal (0.5 g fat/kg body weight + 136 g carbohydrate, 60 g sucrose)
Trial: 29652551
Drug: 3000 mg
RxNorm normalized name: talc 3000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3000 mg of fish-derived n-3 eicosapentaenoic and docosahexaenoic acids
Trial: 28912192
Drug: Pharmacological cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacological cervical ripening with Propess system (10 mg of dinoprostone, Ferring SAS, France) before oxytocin administration
Trial: 21443600
Drug: Alitretinoin 40
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alitretinoin 40 mg after fasting (treatment A)
Trial: 21443600
Drug: Alitretinoin 40
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alitretinoin 40 mg after a standard breakfast (treatment B)
Trial: 19563951
Drug: Azithromycin 600
RxNorm normalized name: azithromycin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 600 mg once daily for 3 days and then 600 mg once weekly for 15 weeks
Trial: 19563951
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of statins and acetylsalicylic acid (ASA)
Trial: 17147908
Drug: Antiviral agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral agents (specifically aciclovir)
Trial: 17147908
Drug: Antiviral agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral agents for post-exposure prophylaxis
Trial: 9062617
Drug: etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate 0.3 mg kg‐1 for induction of anaesthesia
Trial: 8400493
Drug: Allopurinol 50
RxNorm normalized name: allopurinol 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allopurinol 50 mg 4 times daily
Trial: 8400493
Drug: DMSO 500
RxNorm normalized name: DMSO
DrugBank: Dimethyl sulfoxide (DB01093)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: DMSO 500 mg 4 times daily
Trial: 2956140
Drug: Rado-Salil ointment
RxNorm normalized name: SALIX
DrugBank: Willow bark (DB14691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rado-Salil ointment
Trial: 27296091
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and omega-3 fatty acid supplements
Trial: 22639959
Drug: Tipifarnib plus
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tipifarnib plus low dose cytarabine (LDAC)
Trial: 22639959
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose cytarabine (LDAC)
Trial: 8369232
Drug: Chlorpromazine (CPZ)
RxNorm normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorpromazine (CPZ) 900 mg to 1800 mg per day, stepwise increase over 12 months
Trial: 8369232
Drug: Orphenadrine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orphenadrine 300 mg per day
Trial: 27612310
Drug: Group intervention
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group intervention (1-hour sessions, 3-5 subjects, twice a week for 12 weeks)
Trial: 27612310
Drug: Personal intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Personal intervention (20-minute sessions, one staff member per participant, twice a week for 12 weeks)
Trial: 19176895
Drug: Donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks)
Trial: 17377162
Drug: Evaluation and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evaluation and treatment options for intermittent claudication, including potential revascularization.
Trial: 15592331
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg twice daily for 3 days
Trial: 11380714
Drug: Amethocaine gel
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amethocaine gel (topical application for 30 minutes)
Trial: 11380714
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (topical application for 30 minutes)
Trial: 8516087
Drug: Sustained‐release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained‐release theophylline administered twice daily
Trial: 3521784
Drug: Control (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (identical clinical care, no adjuvant chemotherapy)
Trial: 10678268
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg urapidil
Trial: 24725169
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg tamsulosin
Trial: 20604720
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg naftopidil
Trial: 20604720
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (240 mg flopropione and 1350 mg extract of Quercus salicina Blume/Quercus stenophylla Makino)
Trial: 31109906
Drug: Antihypertensive drugs
RxNorm normalized name: ANTIHYPERTENSIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihypertensive drugs prescribed in 157 (87%) participants, median of 1 (IQR 1-2) antihypertensive medication.
Trial: 31109906
Drug: Increasing number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing number of antihypertensives.
Trial: 26308286
Drug: Intravitreal triamcinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal triamcinolone (TA) injection
Trial: 19141433
Drug: Personalized SMS
RxNorm normalized name: Samarium Sm-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized SMS and MMS messages sent 2-5 times daily, printed materials, and brief monthly phone calls from a health counselor.
Trial: 19141433
Drug: Monthly printed
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly printed materials about weight control.
Trial: 12871894
Drug: tibolone 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tibolone 1.25 mg